Newron Pharmaceuticals SpA - Asset Resilience Ratio

Latest as of December 2025: 41.67%

Newron Pharmaceuticals SpA (NWRN) has an Asset Resilience Ratio of 41.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CHF16.68 Million

≈ $21.08 Million USD Cash + Short-term Investments

Total Assets

CHF40.02 Million

≈ $50.60 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2025)

This chart shows how Newron Pharmaceuticals SpA's Asset Resilience Ratio has changed over time. Check Newron Pharmaceuticals SpA PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Newron Pharmaceuticals SpA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Newron Pharmaceuticals SpA.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF16.68 Million	41.67%
Total Liquid Assets	CHF16.68 Million	41.67%

Asset Resilience Insights

Very High Liquidity: Newron Pharmaceuticals SpA maintains exceptional liquid asset reserves at 41.67% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Newron Pharmaceuticals SpA Industry Peers by Asset Resilience Ratio

Compare Newron Pharmaceuticals SpA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA American Depositary Shares NASDAQ:ABVX	Biotechnology	2.58%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Palvella Therapeutics, Inc NASDAQ:PVLA	Biotechnology	21.03%
Gempharmatech Co. Ltd. A SHG:688046	Biotechnology	23.95%
Nanjing Vazyme Biotech Co Ltd SHG:688105	Biotechnology	39.89%
ABCELLERA BIOLOGICS F:8QQ	Biotechnology	29.87%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.12%
Climb Bio Inc NASDAQ:CLYM	Biotechnology	66.42%

Annual Asset Resilience Ratio for Newron Pharmaceuticals SpA (2009–2025)

The table below shows the annual Asset Resilience Ratio data for Newron Pharmaceuticals SpA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	41.67%	CHF16.68 Million ≈ $21.08 Million	CHF40.02 Million ≈ $50.60 Million	+37.14pp
2024-12-31	4.53%	CHF2.89 Million ≈ $3.66 Million	CHF63.91 Million ≈ $80.80 Million	-19.68pp
2023-12-31	24.21%	CHF6.26 Million ≈ $7.92 Million	CHF25.87 Million ≈ $32.70 Million	-0.93pp
2022-12-31	25.14%	CHF9.35 Million ≈ $11.82 Million	CHF37.20 Million ≈ $47.02 Million	+6.17pp
2021-12-31	18.97%	CHF9.57 Million ≈ $12.11 Million	CHF50.49 Million ≈ $63.83 Million	-16.26pp
2020-12-31	35.23%	CHF18.04 Million ≈ $22.80 Million	CHF51.20 Million ≈ $64.73 Million	+6.85pp
2019-12-31	28.38%	CHF17.11 Million ≈ $21.63 Million	CHF60.29 Million ≈ $76.22 Million	+1.33pp
2018-12-31	27.05%	CHF16.23 Million ≈ $20.52 Million	CHF60.00 Million ≈ $75.85 Million	+0.43pp
2017-12-31	26.62%	CHF19.44 Million ≈ $24.58 Million	CHF73.02 Million ≈ $92.32 Million	+20.40pp
2016-12-31	6.22%	CHF3.52 Million ≈ $4.45 Million	CHF56.59 Million ≈ $71.55 Million	-4.87pp
2015-12-31	11.09%	CHF4.92 Million ≈ $6.22 Million	CHF44.38 Million ≈ $56.11 Million	-7.65pp
2014-12-31	18.74%	CHF6.95 Million ≈ $8.78 Million	CHF37.07 Million ≈ $46.87 Million	+1.48pp
2013-12-31	17.26%	CHF5.46 Million ≈ $6.90 Million	CHF31.62 Million ≈ $39.97 Million	+9.10pp
2012-12-31	8.16%	CHF3.64 Million ≈ $4.60 Million	CHF44.65 Million ≈ $56.45 Million	+4.30pp
2009-12-31	3.85%	CHF1.60 Million ≈ $2.03 Million	CHF41.68 Million ≈ $52.69 Million	--

pp = percentage points

About Newron Pharmaceuticals SpA

SW:NWRN Switzerland Biotechnology

Market Cap

$304.60 Million

CHF240.93 Million CHF

Market Cap Rank

#14790 Global

#156 in Switzerland

Share Price

CHF11.58

Change (1 day)

+1.40%

52-Week Range

CHF6.70 - CHF30.40

All Time High

CHF30.40